Changes of topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1501-1506

  Tinari, Nicola ^a   Lattanzio, Rossano ^a   Natoli, Clara ^a   Cianchetti, Ettore ^a   Angelucci, Domenico ^a   Ricevuto, Enrico ^b   Ficorella, Corrado ^b   Marchetti, Paolo ^b   Alberti, Saverio ^a   Piantelli, Mauro ^a   Iacobelli, Stefano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; FEC PROTOCOL; TUMOR ANTIGEN;

ADULT; ARTICLE; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RELAPSE; RELAPSE FREE SURVIVAL; ADJUVANT THERAPY; AGED; CANCER INVASION; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; STEREOISOMERISM; TUMOR RECURRENCE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; RECEPTOR, ERBB-2; STEREOISOMERISM;

EID: 33645079372     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0978     Document Type: Article

References (47)

1. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Surv 1994;20:241-64.
2. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:71-85.
3. Ellis P, Smith I, Ashley S, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998;16:107-14.
4. Bonadonna G, Valagussa P, Brambilla C, et al. Preoperative chemotherapy in operable breast cancer. Lancet 1993;341:1485.
5. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
6. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52.
7. Smith IE, Al Moundhri M. Primary chemotherapy in breast cancer. Biomed Pharmacother 1998;52:116-21.
8. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
9. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
10. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-8.
11. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
12. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 2002;3:235-43.
13. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal drugs. Annu Rev Pharmacol Toxicol 1994;34:191-218.
14. Di Leo A, Isola J. Topoisomerase IIα as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 2003;4:179-86.
15. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II-α immunoreactivity as a marker of aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
16. Fry AM, Chresta CM, Davies SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991;51:6592-5.
17. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987;47:3973-9.
18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
20. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
21. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
22. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
23. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II α co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
24. Järvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
25. MacGrogan G, Rudolph P, de Mascarel I, et al. DNA topoisomerase IIα expression and response to primary chemotherapy in breast cancer. Br J Cancer 2003;89:666-71.
26. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-7.
27. Park K, Kim J, Lim S, Han S. Topoisomerase IIα (TopoII) and HER-2 amplification in breast cancer and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39:631-4.
28. Petit T, Wilt M, Velten M, et al. Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase IIα status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004;40:205-11.
29. Martin-Richard M, Muñoz M, Albanell J, et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004;66:388-94.
30. Burcombe RJ, Makris A, Wilson G, et al. Evaluation of topoisomerase IIα as a predictor of clinical and pathological response to neoadjuvant chemotherapy in operable breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;1785.
31. Dhawan V, Swaffar DS. A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIα. Anticancer Drugs 1999;10:397-404.
32. Bofin M, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates of breast carcinomas. Cytopathology 2003;14:314-21.
33. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
34. Depowski PL, Rosenthal SI, Brien TP, et al. Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Mod Pathol 2000;13:542-7.
35. Rudolph P, MacGrogan G, Bonichon F, et al. Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 1999;55:61-71.
36. Makris A, Powles TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593-600.
37. Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686-92.
38. Daidone MG, Silvestrini R, Luisi A, et al. Changes in biological markers after primary chemotherapy for breast cancer. Int J Cancer 1995;61:301-5.
39. Frassoldati A, Adami F, Banzi C, et al. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1997;44:185-92.
40. Linn SC, Pinedo HM, van ArkOtte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997;71:787-95.
41. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27:251-5.
42. Volm M. Multidrug resistance and its reversal. Anticancer Res 1998;18:2905-17.
43. Tew KD. Gluthatione-associated enzymes in anticancer drug resistance. Cancer Res 1994;15:4313-20.
44. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural produce toxins. Cancer Res 1997;57:15232-7.
45. Renes J, De Vries EGE, Nuenhuis EF, Jansen PLM, Muller M. MATP- and gluthatione-dependent transport of chemotherapeutic drugs by the multi-drug resistance protein MRP1. Br J Pharmacol 1999;126:681-8.
46. Fedier A, Schwarz A, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001;93:571-6.
47. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000;18:87-93.